A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This study evaluates the safety of acalabrutinib and vistusertib when taken in combination.
Epistemonikos ID: c4f50cf62f4e407098e55a93b0048681df38afc7
First added on: May 20, 2024